Anti-VEGF in retinopathy of prematurity, need to titrate

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 3, 2013, Pages 2027-

  Vavvas, Demetrios G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN INHIBITOR; ANTIBODY; HYBRID PROTEIN; OXYGEN; VASCULOTROPIN A;

ARTICLE; CRYOABLATION; DRUG MONITORING; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GROWTH, DEVELOPMENT AND AGING; NOTE; RETINA; RETINA BLOOD VESSEL; RETINA DISEASE;

ANIMALS; ANTIBODIES; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; RECOMBINANT FUSION PROTEINS; RETINA; RETINAL DISEASES; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84875423712     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-11948     Document Type: Article

References (4)

1. Smith LE. Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci. 2008;49:5177-5182.
2. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3{thorn}retinopathy of prematurity. N Engl J Med. 2011;364:603-615.
3. Lutty GA, McLeod DS, Bhutto I, Wiegand SJ. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci. 2011;52:4039-4047.
4. McCloskey M, Wang H, Jiang Y, SmithGW, Strange J, Hartnett ME. Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of ROP. Invest Ophthalmol Vis Sci. 2013;54:2020-2026.